Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention
Trial Parameters
Brief Summary
Atrial fibrillation (AF) is a major public health problem. The efficacy of the existing techniques is limited in the more aggressive forms. It is therefore necessary to develop approaches, in particular the identification of relevant biomarkers, to prevent the onset, recurrence or progression of AF in at-risk patients. The objective of this study is to describe the longitudinal metabolic and biomolecular signature of AF in patients eligible for cardiac ablation.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years, all genders, and ethnic origins * Free, informed, and written consent signed * Person affiliated to or benefiting from a social security scheme Exclusion Criteria: * Age \< 18 years * Lack of informed consent * Gestating women (pregnancy test carried out as part of care for FA patients, contraception, or menopause for women in control groups) * Persons under administrative or judicial protection * Endocarditis or pericarditis in progress or within the 3 last months * Active tumor pathology (benign or malignant) * Chronic inflammation or autoimmune disease * Chronic liver disease * Myocardial infarction within the last 8 weeks